We continue to monitor COVID-19, flu and other respiratory viruses in our communities. Read the most current information about prevention, testing and where to go if you're sick.

COVID-19 Information

BJC Medical Group Convenient Care at Chesterfield

Getting access to the right care in the right setting is an important part of keeping you and your family healthy. BJC Medical Group Convenient Care in the Chesterfield Outpatient Center provides treatment for minor illnesses and injuries at the same cost as a primary care office visit. Vaccinations, school or sports physicals and COVID-19 testing available.

With online self-scheduling, reserving a time close to home has never been easier.

Reserve a Time

Common ailments treated include:

  • Allergies 
  • Cough, cold or flu symptoms
  • Ear infection
  • Eye irritation
  • Fever
  • Insect bites or rashes
  • Joint sprains
  • Minor muscle strains
  • Minor scrapes, cuts or bruises
  • Painful urination
  • Sinus symptoms
  • Sore throat

Laboratory testing and radiology services are provided by Missouri Baptist Medical Center and offered with a physician’s order.

BJC Emergency Care

If you need more serious care, Missouri Baptist Medical Center has both an adult and pediatric emergency unit. The child-focused, family-centered pediatric emergency unit is staffed 24-7 by specialty-trained pediatric nurses and Washington University pediatricians from St. Louis Children’s Hospital.

Map and directions to Missouri Baptist Medical Center Emergency Room.

BJC Medical Group Convenient Care in Chesterfield Outpatient Center

15838 Fountain Plaza Drive
Chesterfield, Missouri 63017

Convenient Care: 636-484-5277

Reserve a Time

Visit BJC Convenient Care for all locations.

BJC Medical Group accepts a wide variety of health insurance plans. We also accept primary care co-pay, the amount indicated on your insurance card. Cash, personal checks, Visa, MasterCard and American Express are accepted.

MoBap Offers a New FDA-Approved Treatment for People With Advanced Prostate Cancer

Prostate cancer is the second leading cause of cancer death in American men, with one in eight males diagnosed in their lifetime.

On March 23, 2022, prostate cancer treatment for those with advanced disease took a step forward with the FDA approving the first targeted therapy for the treatment of progressive, PSMA-positive prostate cancer that has spread or metastasized to other parts of the body.

Vincent Joe, MD, a radiation oncologist on staff at Missouri Baptist Medical Center, explained that the new medication is a type of precision radiotherapy that targets a specific protein on the prostate cancer cells called prostate-specific membrane antigen, or PSMA. When it attaches, the medicine delivers a concentrated form of radiotherapy directly to the cancer cells no matter where they are in the body.

"This therapy is designed for those whose cancer isn't responding to standard treatment options like chemotherapy or anti-testosterone hormone treatment. This new therapy has been shown to extend the life of people with terminal prostate cancer and slow down cancer's spread," Dr. Joe said.

For patients, the first step is to have a PSMA positron emission tomography (PET) scan. This test can tell doctors if the prostate cancer has spread to other parts of the body, as well as help to determine their
eligibility for the new drug.

Dr. Joe added that if a patient qualifies for the new therapy, it's given through an IV infusion. "Patients receive an infusion every six weeks for a total of six infusions over 30 weeks. In between treatments, we check blood work to make sure they are tolerating the medication and can modify the dosage if necessary."

Missouri Baptist Medical Center is one of three sites in Missouri that is currently offering this treatment.

"While this treatment is not a cure, it is a very promising therapy for patients who have exhausted other options," Dr. Joe said.

For more information about this treatment, call: 314-996-5199.